BIOMAT Database Logo BIOMAT Database Logo

Substituted 4-morpholine N-arylsulfonamides as γ-secretase inhibitors. 2016

Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Department of Medicinal Chemistry, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: zhiqiang.zhao@merck.com.

The design, synthesis, SAR, and biological profile of a substituted 4-morpholine sulfonamide series of γ-secretase inhibitors (GSIs) were described. In several cases, the resulting series of GSIs reduced CYP liabilities and improved γ-secretase inhibition activity compared to our previous research series. Selected compounds demonstrated significant reduction of amyloid-β (Aβ) after acute oral dosing in a transgenic animal model of Alzheimer's disease (AD).

UI MeSH Term Description Entries
D008297 Male Males
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability.
November 2009, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
N-(5-chloro-2-(hydroxymethyl)-N-alkyl-arylsulfonamides as gamma-secretase inhibitors.
August 2007, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.
November 2012, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Identification of arylsulfonamides as Aquaporin 4 inhibitors.
March 2007, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
January 2006, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
γ-Secretase inhibitors and modulators.
December 2013, Biochimica et biophysica acta,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Part 3: Notch-sparing γ-secretase inhibitors: SAR studies of 2-substituted aminopyridopyrimidinones.
May 2016, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.
November 2010, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase.
February 2005, Bioorganic & medicinal chemistry letters,
Zhiqiang Zhao, and Dmitri A Pissarnitski, and Hubert B Josien, and Thomas A Bara, and John W Clader, and Hongmei Li, and Mark D McBriar, and Murali Rajagopalan, and Ruo Xu, and Giuseppe Terracina, and Lynn Hyde, and Lixin Song, and Lili Zhang, and Eric M Parker, and Rebecca Osterman, and Alexei V Buevich
Identification of presenilin 1-selective γ-secretase inhibitors with reconstituted γ-secretase complexes.
June 2011, Biochemistry,
Copied contents to your clipboard!